| abstract |
The present invention relates to a pharmaceutical composition for the prevention and treatment, human or animal, of leishmaniasis, formed:n a) by the protein Chimera Q, or a variant containing modifications or substitutions of preserved amino acids thereof; b) by protein Q in isolated form or combined with any physiological adjuvant. n The invention also relates to a vaccine against the Leishmania parasite, formedn a) by protein Q or a variant of this protein that differs from protein Q in preserved amino acids, or b) by protein Q in isolated form or combined with a physiological adjuvant. n Optionally, in the composition or vaccine of the invention, protein Q may be combined with the protein LiHsp70. Also, instead of protein Q, a DNA vector bearing the sequence that codes for the protein Q may be used. |